{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:09:45Z","timestamp":1791828585036,"version":"4.3.4"},"reference-count":53,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019016","name":"Assessment of SpondyloArthritis international Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019016","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.rdc.2025.05.004","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T15:36:31Z","timestamp":1748964991000},"page":"433-445","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Axial Psoriatic Arthritis"],"prefix":"10.1016","volume":"51","author":[{"given":"Denis","family":"Poddubnyy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.rdc.2025.05.004_bib1","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.3899\/jrheum.171094","article-title":"Influence of axial involvement on clinical characteristics of psoriatic arthritis: analysis from the corrona psoriatic arthritis\/spondyloarthritis registry","volume":"45","author":"Mease","year":"2018","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.rdc.2025.05.004_bib2","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3899\/jrheum.210662","article-title":"Evaluation of clinical diagnosis of axial psoriatic arthritis (PsA) or elevated patient-reported spine pain in CorEvitas\u2019 PsA\/Spondyloarthritis Registry","volume":"49","author":"Ogdie","year":"2022","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.rdc.2025.05.004_bib3","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.semarthrit.2021.06.006","article-title":"Axial involvement in psoriatic arthritis: an update for rheumatologists","volume":"51","author":"Poddubnyy","year":"2021","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.rdc.2025.05.004_bib4","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s40265-023-01857-w","article-title":"Managing psoriatic arthritis patients presenting with axial symptoms","volume":"83","author":"Poddubnyy","year":"2023","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.rdc.2025.05.004_bib5","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.rdc.2020.01.009","article-title":"Axial psoriatic arthritis: a distinct clinical entity in search of a definition","volume":"46","author":"Michelena","year":"2020","journal-title":"Rheum Dis Clin N Am"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.004_bib6","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0049-0172(73)90035-8","article-title":"Psoriatic arthritis","volume":"3","author":"Moll","year":"1973","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.rdc.2025.05.004_bib7","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X211057975","article-title":"Axial involvement in psoriatic arthritis cohort (AXIS): the protocol of a joint project of the assessment of SpondyloArthritis international Society (ASAS) and the group for research and assessment of psoriasis and psoriatic arthritis (GRAPPA)","volume":"13","author":"Poddubnyy","year":"2021","journal-title":"Therapeutic advances in musculoskeletal disease"},{"issue":"4","key":"10.1016\/j.rdc.2025.05.004_bib8","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00103-020-03110-1","article-title":"[Frequencies of musculoskeletal symptoms and disorders in the population-based German National Cohort (GNC)]","volume":"63","author":"Schmidt","year":"2020","journal-title":"Bundesgesundheitsblatt - Gesundheitsforsch - Gesundheitsschutz"},{"issue":"11","key":"10.1016\/j.rdc.2025.05.004_bib9","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1136\/annrheumdis-2019-215589","article-title":"MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group","volume":"78","author":"Maksymowych","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.rdc.2025.05.004_bib10","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1136\/annrheumdis-2021-222081","article-title":"MRI lesions of the spine in patients with axial spondyloarthritis: an update of lesion definitions and validation by the ASAS MRI working group","volume":"81","author":"Baraliakos","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"Supplement_2","key":"10.1016\/j.rdc.2025.05.004_bib11","doi-asserted-by":"crossref","first-page":"ii15","DOI":"10.1093\/rheumatology\/keae558","article-title":"Axial involvement in psoriatic arthritis: is it unique?","volume":"63","author":"Helliwell","year":"2024","journal-title":"Rheumatology"},{"issue":"238","key":"10.1016\/j.rdc.2025.05.004_bib12","first-page":"127","article-title":"Psoriatic arthritis (PSA)--an analysis of 220 patients","volume":"62","author":"Gladman","year":"1987","journal-title":"Q J Med"},{"issue":"6","key":"10.1016\/j.rdc.2025.05.004_bib13","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s11926-007-0074-2","article-title":"Axial disease in psoriatic arthritis","volume":"9","author":"Gladman","year":"2007","journal-title":"Curr Rheumatol Rep"},{"issue":"4","key":"10.1016\/j.rdc.2025.05.004_bib14","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/BOR.0000000000000609","article-title":"Psoriatic spondylitis or ankylosing spondylitis with psoriasis: same or different?","volume":"31","author":"Chandran","year":"2019","journal-title":"Curr Opin Rheumatol"},{"issue":"4","key":"10.1016\/j.rdc.2025.05.004_bib15","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1136\/annrheumdis-2016-209853","article-title":"Axial disease in psoriatic arthritis study: defining the clinical and radiographic phenotype of psoriatic spondyloarthritis","volume":"76","author":"Jadon","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.rdc.2025.05.004_bib16","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.semarthrit.2021.03.007","article-title":"Axial disease in psoriatic arthritis: the presence and progression of unilateral grade 2 sacroiliitis in a psoriatic arthritis cohort","volume":"51","author":"Feld","year":"2021","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.rdc.2025.05.004_bib17","doi-asserted-by":"crossref","first-page":"809","DOI":"10.3899\/jrheum.091059","article-title":"Risk factors for axial inflammatory arthritis in patients with psoriatic arthritis","volume":"37","author":"Chandran","year":"2010","journal-title":"J Rheumatol"},{"issue":"suppl 9","key":"10.1016\/j.rdc.2025.05.004_bib18","article-title":"Characteristics of patients with psoriatic arthritis presenting with axial involvement: results of a prospective international multicenter study (AXIS) [abstract]","volume":"76","author":"Torgutalp","year":"2024","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"10.1016\/j.rdc.2025.05.004_bib19","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nrrheum.2017.188","article-title":"Enthesitis: from pathophysiology to treatment","volume":"13","author":"Schett","year":"2017","journal-title":"Nat Rev Rheumatol"},{"issue":"9","key":"10.1016\/j.rdc.2025.05.004_bib20","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11926-017-0681-5","article-title":"Mechanism of new bone formation in axial spondyloarthritis","volume":"19","author":"Poddubnyy","year":"2017","journal-title":"Curr Rheumatol Rep"},{"issue":"12","key":"10.1016\/j.rdc.2025.05.004_bib21","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/s41584-019-0294-7","article-title":"The IL-23-IL-17 pathway as a therapeutic target in axial spondyloarthritis","volume":"15","author":"Sieper","year":"2019","journal-title":"Nat Rev Rheumatol"},{"issue":"9","key":"10.1016\/j.rdc.2025.05.004_bib22","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","article-title":"Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study","volume":"77","author":"Baeten","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.rdc.2025.05.004_bib23","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/art.40728","article-title":"Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"10.1016\/j.rdc.2025.05.004_bib24","doi-asserted-by":"crossref","first-page":"e715","DOI":"10.1016\/S2665-9913(21)00105-3","article-title":"Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies","volume":"3","author":"Mease","year":"2021","journal-title":"Lancet Rheumatol"},{"issue":"6","key":"10.1016\/j.rdc.2025.05.004_bib25","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1007\/s40744-023-00592-8","article-title":"Efficacy of guselkumab on axial-related symptoms through up to 2 years in adults with active psoriatic arthritis in the phase 3, randomized, placebo-controlled DISCOVER-2 Study","volume":"10","author":"Mease","year":"2023","journal-title":"Rheumatol Ther"},{"issue":"2","key":"10.1016\/j.rdc.2025.05.004_bib26","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002513","article-title":"Characterising the axial phenotype of psoriatic arthritis: a study comparing axial psoriatic arthritis and ankylosing spondylitis with psoriasis from the REGISPONSER registry","volume":"8","author":"Michelena","year":"2022","journal-title":"RMD Open"},{"issue":"5","key":"10.1016\/j.rdc.2025.05.004_bib27","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1007\/s12325-023-02475-4","article-title":"Genetic and molecular distinctions between axial psoriatic arthritis and radiographic axial spondyloarthritis: post hoc analyses from four phase 3 clinical trials","volume":"40","author":"Kavanaugh","year":"2023","journal-title":"Adv Ther"},{"issue":"12","key":"10.1016\/j.rdc.2025.05.004_bib28","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41584-023-01038-9","article-title":"Predominant ligament-centric soft-tissue involvement differentiates axial psoriatic arthritis from ankylosing spondylitis","volume":"19","author":"McGonagle","year":"2023","journal-title":"Nat Rev Rheumatol"},{"issue":"Supplement_2","key":"10.1016\/j.rdc.2025.05.004_bib29","doi-asserted-by":"crossref","first-page":"ii7","DOI":"10.1093\/rheumatology\/keae568","article-title":"Focusing on ligamentous soft tissue inflammation for the future understanding of early axial psoriatic arthritis","volume":"63","author":"Abacar","year":"2024","journal-title":"Rheumatology"},{"key":"10.1016\/j.rdc.2025.05.004_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.crad.2024.08.014","article-title":"The \u2018Tree trunk and root\u2019 model: key imaging findings may anatomically differentiate axial psoriatic arthritis and DISH from axial spondyloarthropathy","volume":"80","author":"Hussein","year":"2025","journal-title":"Clin Radiol"},{"issue":"6","key":"10.1016\/j.rdc.2025.05.004_bib31","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41584-018-0006-8","article-title":"Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison","volume":"14","author":"Feld","year":"2018","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.004_bib32","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002837","article-title":"Comparison of patients with axial PsA and patients with axSpA and concomitant psoriasis: an analysis of the German register RABBIT-SpA","volume":"9","author":"Regierer","year":"2023","journal-title":"RMD Open"},{"issue":"11","key":"10.1016\/j.rdc.2025.05.004_bib33","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1136\/ard-2022-222562","article-title":"Early identification of axial psoriatic arthritis among patients with psoriasis: a prospective multicentre study","volume":"81","author":"Proft","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.rdc.2025.05.004_bib34","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1093\/rheumatology\/kead566","article-title":"The ATTRACT study: screening for the early identification of axial psoriatic arthritis in a cohort of Italian psoriatic patients","volume":"63","author":"Luchetti Gentiloni","year":"2024","journal-title":"Rheumatology"},{"issue":"Suppl 3","key":"10.1016\/j.rdc.2025.05.004_bib35","doi-asserted-by":"crossref","first-page":"iii22","DOI":"10.1136\/ard.2006.058453","article-title":"Clinical, radiological, and functional assessment in psoriatic arthritis: is it different from other inflammatory joint diseases?","volume":"65","author":"Gladman","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.rdc.2025.05.004_bib36","first-page":"270","article-title":"Clinical and genetic associations of radiographic sacroiliitis and its different patterns in psoriatic arthritis","volume":"35","author":"Haroon","year":"2017","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.004_bib37","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/rheumatology\/keg475","article-title":"Clinical assessment of sacroiliitis and HLA-B27 are poor predictors of sacroiliitis diagnosed by magnetic resonance imaging in psoriatic arthritis","volume":"43","author":"Williamson","year":"2004","journal-title":"Rheumatology"},{"key":"10.1016\/j.rdc.2025.05.004_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2021.101670","article-title":"Clinical features of psoriatic arthritis","author":"Kishimoto","year":"2021","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"6","key":"10.1016\/j.rdc.2025.05.004_bib39","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1093\/rheumatology\/kez629","article-title":"Axial disease in psoriatic arthritis","volume":"59","author":"Helliwell","year":"2020","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.rdc.2025.05.004_bib40","article-title":"BASDAI versus ASDAS in evaluating axial involvement in patients with psoriatic arthritis: a pooled analysis of two phase 3 studies","volume":"8","author":"Baraliakos","year":"2024","journal-title":"Rheumatol Adv Pract"},{"issue":"2","key":"10.1016\/j.rdc.2025.05.004_bib41","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3899\/jrheum.2023-0504","article-title":"Use of the bath ankylosing spondylitis disease activity index in patients with psoriatic arthritis with and without axial disease","volume":"51","author":"Reddy","year":"2024","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.004_bib42","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/art.40726","article-title":"Special article: 2018 American College of rheumatology\/National psoriasis foundation guideline for the treatment of psoriatic arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"10.1016\/j.rdc.2025.05.004_bib43","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for research and assessment of psoriasis and psoriatic arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"10.1016\/j.rdc.2025.05.004_bib44","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/ard-2024-225531","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update","volume":"83","author":"Gossec","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.004_bib45","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/ard-2022-223296","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","volume":"82","author":"Ramiro","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2025.05.004_bib46","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/annrheumdis-2019-eular.2932","article-title":"Secukinumab improves axial manifestations in patients with psoriatic arthritis and inadequate response to NSAIDs: primary analysis of the MAXIMISE trial","volume":"78","author":"Baraliakos","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2025.05.004_bib47","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X231189005","article-title":"The effect of ixekizumab on axial manifestations in patients with psoriatic arthritis from two phase III clinical trials: SPIRIT-P1 and SPIRIT-P2","volume":"15","author":"Deodhar","year":"2023","journal-title":"Therapeutic advances in musculoskeletal disease"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.004_bib48","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13075-023-03027-5","article-title":"Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies","volume":"25","author":"Baraliakos","year":"2023","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"10.1016\/j.rdc.2025.05.004_bib49","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-048647","article-title":"Efficacy of tofacitinib in reduction of inflammation detected on MRI in patients with Psoriatic ArthritiS presenTing with axial involvement (PASTOR): protocol of a randomised, double-blind, placebo-controlled, multicentre trial","volume":"11","author":"Proft","year":"2021","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.004_bib50","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001149","article-title":"Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naive active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials","volume":"6","author":"Helliwell","year":"2020","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.004_bib51","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1186\/s13063-022-06589-y","article-title":"Efficacy and safety of guselkumab in biologic-naive patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial","volume":"23","author":"Gladman","year":"2022","journal-title":"Trials"},{"issue":"12","key":"10.1016\/j.rdc.2025.05.004_bib52","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1136\/ard-2024-225933","article-title":"Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b\/3 trials","volume":"83","author":"Brown","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2025.05.004_bib53","article-title":"Development of extramusculoskeletal manifestations in upadacitinib-treated patients with psoriatic arthritis or axial spondyloarthritis","author":"Poddubnyy","year":"2024","journal-title":"Arthritis Rheumatol"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X25000274?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X25000274?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:16:42Z","timestamp":1752711402000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X25000274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0889857X25000274"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2025.05.004","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Axial Psoriatic Arthritis","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2025.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}